As the administration pushes for a return to US manufacturing, outsourcing agreements with domestic manufacturers are ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

The biotech giant's new facility is part of a larger U.S. investment strategy, though it may roll back its buildout if the ...

Orionis Biosciences, a privately held company, announced a second multi-year collaboration with Genentech, a member of the ...

Genentech, considered one of the biotech industry’s founding companies, plans to build a $700 million, 700,000-square-foot ...

HOLLY SPRINGS, N.C. -- Genentech, a leading biotechnology company based in San Francisco, is set to build a $700 million ...

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients ...

A new promo for Roche’s blockbuster hemophilia A drug Hemlibra focuses less on those with the genetic bleeding disorder and ...

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with ...